Biopharma en 2025: Perspectivas para Medicamentos para la Obesidad, Precios de Medicamentos, Regulación y Más
Metabolic medicine emerged as a dominant theme in the life sciences industry in 2024, with Novo Nordisk and Eli Lilly experiencing significant revenue growth from their metabolic drugs Wegovy and Zepbound. This success has sparked increased interest in metabolic drug research, attracting new contenders aiming to develop innovative products for weight loss. While the obesity … Leer más
